ClinicalTrials.gg
CompletedNCT02962960Updated Jan 12, 2023Results posted

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

A Phase 2 interventional study of Anifrolumab and Placebo in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 14 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-12.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
14th of 20
36 · median 159
Started
2017
the only one that year
Phase 2
6 of 20
2 open now
Registered
6th of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 14th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 6th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This study will be conducted to characterize pharmacokinetics, pharmacodynamics, safety, and tolerability of anifrolumab given via the subcutaneous (SC) route of administration in adult Systemic Lupus Erythematosus (SLE) subjects with a type I Interferon (IFN) test high result and active skin manifestations while receiving Standard of Care (SOC) treatment. In addition, the efficacy of anifrolumab on SLE skin manifestations will be characterized.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 through 70 years
  2. Diagnosis of paediatric or adult SLE for > 24 weeks and fulfilling ≥4 of the 11 American College of Rheumatology (ACR) classification criteria with at least one being:

    • Positive antinuclear antibody (ANA) or
    • Elevated anti-dsDNA antibodies or
    • anti-Smith (anti-Sm) antibodies
  3. Interferon high test result
  4. Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score ≥ 10
  5. Currently receiving at least 1 of the following for treatment of SLE:

    • Oral prednisone or equivalent of ≤40 mg/day for a minimum of 2 weeks prior to signing the Form (ICF) and with stable dose for at least 2 weeks prior to randomization
    • Any of the following medications for at least 12 weeks prior to signing the ICF, and at a stable doses for at least 8 weeks prior to randomization: (i) Azathioprine ≤200 mg/day (ii) Antimalarials (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150 mg/day
  6. Must not have signs of active or latent tuberculosis (TB).
  7. Must not be pregnant or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  1. Active severe or unstable neuropsychiatric SLE
  2. Active severe SLE-driven renal disease
  3. Any severe herpes infection at any time
  4. Virus (HBV), Virus (HCV), or infection.
  5. Known history of a primary immunodeficiency (splenectomy, or any underlying condition predisposing for infection
  6. Receipt of any investigation product within 4 weeks or 5 half -lives prior to signing of the ICF
  7. History of cancer, apart from:

    • Squamous or basal cell carcinoma of the skin if successfully treated.
    • Cervical cancer in situ if successfully treated
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Anifrolumab - Lower dose

    1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50

    Drug: Anifrolumab

  • Placebo comparator
    Placebo matching for lower dose of Anifrolumab

    1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50

    Drug: Placebo

  • Experimental
    Anifrolumab - Higher dose

    2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50

    Drug: Anifrolumab

  • Placebo comparator
    Placebo matching for higher dose of Anifrolumab

    2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50

    Drug: Placebo

Interventions

  • subcutaneous administration every 2 weeks from week 0 to week 50

  • DrugPlacebo

    subcutaneous administration every two weeks from week 0 to week 50

06

What researchers measure

Primary outcomes

  1. Maximum Concentration of Anifrolumab in Serum After First Dose

    Maximum concentration (Cmax) of anifrolumab is based on sample collected 5 to 8 days after the first dose of strudy treatment.

    Time frame: Week 0

  2. Steady-state Serum Trough (Predose) Concentration (Ctrough) of Anifrolumab

    Steady-state serum through concentration (Ctrough) is based on sample collected at Week 12 prior to dosing of study treatment (predose).

    Time frame: Week 12

  3. 21-gene Type 1 IFN Signature Score (Fold-change)

    21-gene type I IFN signature score (fold change) is based on samples collected both at baseline and Week 12 prior to dosing of study treatment. Levels of 21-gene type I IFN pharmacodynamics signature is derived as relative to a pooled normal control.

    Time frame: Week 12

  4. 21-gene Type 1 IFN Neutralization Ratio (Percent Suppression of Fold Change)

    21-gene type I IFN signature score (fold change) is based on samples collected both at baseline and Week 12 prior to dosing of study treatment. For each individual participant and assessment, the level of 21-gene type I IFN pharmacodynamics signature is derived as relative to a pooled normal control, as the median of 100-(((baseline-Week 12)/baseline)\*100) for the 21 genes. At a population level, the results are presented as mean the above.

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants With Antidrug Antibody (ADA)

    Post-baseline ADA incidence based on the number of participants with Antidrug antibody (ADA)

    Time frame: Baseline to Week 52

  2. Number of Participants With Neutralizing Antibodies (nAb)

    Incidence of detectable nAb in post-baseline ADA positive participants.

    Time frame: Baseline to Week 52

  3. Number AEs (Adverse Events) and SAEs (Serious Adverse Events), Including Adverse Events of Special Interest (AESI)

    Number of participants with any AEs (Adverse events), any SAEs (serious adverse events), and any adverse events of special interest (AESI) are summarized. More details are reported in the Adverse Events section.

    Time frame: Baseline to Week 52

  4. Change From Baseline for Vital Signs

    Change from baseline for vital signs.

    Time frame: Baseline to Week 60

  5. Change From Baseline for Physical Examination

    Physical examination is reported as change from baseline in body weight.

    Time frame: Baseline to Week 60

  6. Change From Baseline for 12-lead ECG

    The 12-lead ECG measurements were assessed by the investigators, and reported as normal, abnormal (not clinically significant \[NCS\]), abnormal (clinically significant \[CS\]), or not done.

    Time frame: Baseline to Week 52

  7. Value of Haemoglobin Blood Test to Detect Change From Baseline

    Change from baseline in haemoglobin blood tests are reported.

    Time frame: Baseline to Week 60

  8. Value of Haematology Blood Tests to Detect Change From Baseline

    Change from baseline in haematology blood tests (leucocytes \[particle concentration\], platelets \[particle concentration\]) are reported.

    Time frame: Baseline to Week 60

  9. Value of Protein-creatinine Urinalysis Test to Detect Change From Baseline

    Change from baseline in protein-creatinine ratio urinalysis tests are reported.

    Time frame: Baseline to Week 60

  10. Value of Total Protein Urinalysis Test to Detect Change From Baseline

    Change from baseline in total protein urinalysis tests are reported.

    Time frame: Baseline to Week 60

  11. Value of Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)

    Change from baseline in clinical chemistry blood tests (Alanine Aminotransferase, Aspartate Aminotransferase) are reported.

    Time frame: Baseline to Week 60

  12. Value of Creatinine Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)

    Change from baseline in clinical creatinine chemistry blood tests (serum) are reported.

    Time frame: Baseline to Week 60

  13. Value of Inflammatory Marker Panel Blood Tests to Detect Change From Baseline

    Change from baseline in the Erythrocyte Sedimentation Rate (ESR) inflammatory marker is reported.

    Time frame: Baseline to Week 60

  14. Value of Autoantibody Blood Panel Blood Tests to Detect Change From Baseline

    Change from baseline in Anti-Double Stranded DNA IgG (anti-dsDNA) is reported.

    Time frame: Baseline to Week 60

  15. Number of Participants With Positive Hepatitis B Core Antibody Post-baseline.

    Change from screening in Hepatitis B core antibody was monitored during the study for participants tested positive at screening.

    Time frame: Baseline to Week 60

07

Results

Posted Dec 18, 2019

Participant flow

Participants type I Interferon (IFN) test-high Systemic Lupus Erythematosus (SLE) subjects with active skin manifestations while receiving Standard of Care (SOC) treatment were eligible for the study.

Participant flow — Overall Study
MilestoneAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
Started14139
Completed11119
Not completed320
Withdrew: Withdrawal by subject110
Withdrew: Adverse event110
Withdrew: Protocol violation100

Outcome measures

PrimaryMaximum Concentration of Anifrolumab in Serum After First Dose

Maximum concentration (Cmax) of anifrolumab is based on sample collected 5 to 8 days after the first dose of strudy treatment.

Time frame:
Week 0
Reported as:
Geometric mean · mcg/mL
Maximum Concentration of Anifrolumab in Serum After First Dose
mcg/mLAnifrolumab - Lower DoseAnifrolumab - Higher Dose
Maximum Concentration of Anifrolumab in Serum After First Dose14.058 ± 49.815128.115 ± 74.4916
PrimarySteady-state Serum Trough (Predose) Concentration (Ctrough) of Anifrolumab

Steady-state serum through concentration (Ctrough) is based on sample collected at Week 12 prior to dosing of study treatment (predose).

Time frame:
Week 12
Reported as:
Geometric mean · mcg/mL
Steady-state Serum Trough (Predose) Concentration (Ctrough) of Anifrolumab
mcg/mLAnifrolumab - Lower DoseAnifrolumab - Higher Dose
Steady-state Serum Trough (Predose) Concentration (Ctrough) of Anifrolumab15.618 ± 81.359516.926 ± 9205.6677
Primary21-gene Type 1 IFN Signature Score (Fold-change)

21-gene type I IFN signature score (fold change) is based on samples collected both at baseline and Week 12 prior to dosing of study treatment. Levels of 21-gene type I IFN pharmacodynamics signature is derived as relative to a pooled normal control.

Time frame:
Week 12
Reported as:
Mean · fold change
21-gene Type 1 IFN Signature Score (Fold-change)
fold changeAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
21-gene Type 1 IFN Signature Score (Fold-change)3.2 ± 3.693.5 ± 5.7314.3 ± 6.68
Primary21-gene Type 1 IFN Neutralization Ratio (Percent Suppression of Fold Change)

21-gene type I IFN signature score (fold change) is based on samples collected both at baseline and Week 12 prior to dosing of study treatment. For each individual participant and assessment, the level of 21-gene type I IFN pharmacodynamics signature is derived as relative to a pooled normal control, as the median of 100-(((baseline-Week 12)/baseline)\*100) for the 21 genes. At a population level, the results are presented as mean the above.

Time frame:
Week 12
Reported as:
Mean · percentage neutralization
21-gene Type 1 IFN Neutralization Ratio (Percent Suppression of Fold Change)
percentage neutralizationAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
21-gene Type 1 IFN Neutralization Ratio (Percent Suppression of Fold Change)77.5 ± 24.1680.5 ± 36.6515.1 ± 49.63
SecondaryNumber of Participants With Antidrug Antibody (ADA)

Post-baseline ADA incidence based on the number of participants with Antidrug antibody (ADA)

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Antidrug Antibody (ADA)
ParticipantsAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
Number of Participants With Antidrug Antibody (ADA)110
SecondaryNumber of Participants With Neutralizing Antibodies (nAb)

Incidence of detectable nAb in post-baseline ADA positive participants.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies (nAb)
ParticipantsAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
Number of Participants With Neutralizing Antibodies (nAb)000
SecondaryNumber AEs (Adverse Events) and SAEs (Serious Adverse Events), Including Adverse Events of Special Interest (AESI)

Number of participants with any AEs (Adverse events), any SAEs (serious adverse events), and any adverse events of special interest (AESI) are summarized. More details are reported in the Adverse Events section.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number AEs (Adverse Events) and SAEs (Serious Adverse Events), Including Adverse Events of Special Interest (AESI)
ParticipantsAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
Any adverse event12117
Any serious adverse event420
Any adverse event of special interest511
SecondaryChange From Baseline for Vital Signs

Change from baseline for vital signs.

Time frame:
Baseline to Week 60
Reported as:
Mean · mmHg
Change From Baseline for Vital Signs
mmHgAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Systolic Blood Pressure (mmHg) - Week 12-4.1 ± 12.083 ± 6.63-5.8 ± 13.997.3 ± 8.96
Systolic Blood Pressure (mmHg) - Week 522.1 ± 10.96-1.7 ± 12.963.4 ± 8.5312.5 ± 19.36
Systolic Blood Pressure (mmHg) - Week 604.1 ± 19.70-2.8 ± 14.9112.2 ± 8.614.5 ± 7.14
Diastolic Blood Pressure (mmHg) - Week 12-2.0 ± 10.022.4 ± 6.71-3.8 ± 6.504.3 ± 4.35
Diastolic Blood Pressure (mmHg) - Week 520.1 ± 6.872.9 ± 7.54-0.4 ± 7.136.8 ± 5.38
Diastolic Blood Pressure (mmHg) - Week 603.6 ± 12.23-0.8 ± 6.86-1.0 ± 8.228.8 ± 6.29
SecondaryChange From Baseline for Physical Examination

Physical examination is reported as change from baseline in body weight.

Time frame:
Baseline to Week 60
Reported as:
Mean · kilograms
Change From Baseline for Physical Examination
kilogramsAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Week 12-1.81 ± 2.6741.37 ± 3.1130.7 ± 1.8890.98 ± 2.904
Week 52-2.83 ± 4.6832.52 ± 6.4950.30 ± 3.3383.90 ± 5.608
Week 60-1.81 ± 3.8582.93 ± 6.4631.06 ± 4.0203.60 ± 5.300
SecondaryChange From Baseline for 12-lead ECG

The 12-lead ECG measurements were assessed by the investigators, and reported as normal, abnormal (not clinically significant \[NCS\]), abnormal (clinically significant \[CS\]), or not done.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Change From Baseline for 12-lead ECG
ParticipantsAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Normal baseline - Normal Week 5271053
Normal baseline - Abnormal (NCS) Week 521100
Normal baseline - not done Week 521200
Abnormal (NCS) baseline - Normal Week 522001
Abnormal (NCS) baseline - Abnormal (NCS) Week 521000
Abnormal (NCS) baseline - not done Week 522000
Not done baseline - Normal Week 520000
Not done baseline - Abnormal (NCS) Week 520000
Not done baseline - Not done Week 520000
Normal baseline - Abnormal (CS) Week 520000
Abnormal (NCS) baseline - Abnormal (CS) Week 520000
Not done baseline - Abnormal (CS) Week 520000
Abnormal (CS) baseline - Normal Week 520000
Abnormal (CS) baseline - Abnormal (CS) Week 520000
Abnormal (CS) baseline - Not done Week 520000
Abnormal (CS) baseline - Abnormal (NCS) Week 520000
SecondaryValue of Haemoglobin Blood Test to Detect Change From Baseline

Change from baseline in haemoglobin blood tests are reported.

Time frame:
Baseline to Week 60
Reported as:
Mean · g/L
Value of Haemoglobin Blood Test to Detect Change From Baseline
g/LAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Haemoglobin - Week 12-0.2 ± 9.070.7 ± 7.4-0.5 ± 7.144.8 ± 5.91
Haemoglobin - Week 52-1.1 ± 13.920.1 ± 11.65-4.8 ± 3.837 ± 5.94
Haemoglobin - Week 600.8 ± 12.970 ± 10.43-5.4 ± 5.685.8 ± 6.85
SecondaryValue of Haematology Blood Tests to Detect Change From Baseline

Change from baseline in haematology blood tests (leucocytes \[particle concentration\], platelets \[particle concentration\]) are reported.

Time frame:
Baseline to Week 60
Reported as:
Mean · 10^9/L
Value of Haematology Blood Tests to Detect Change From Baseline
10^9/LAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Leucocytes - Week 120.491 ± 1.58063.165 ± 2.27060.867 ± 1.09991.96 ± 1.9487
Leucocytes - Week 521.041 ± 1.57942.457 ± 2.38910.236 ± 1.01070.080 ± 1.4798
Leucocytes - Week 60-0.012 ± 1.54891.474 ± 1.64900.776 ± 2.17791.23 ± 1.6687
Platelets - Week 127.8 ± 65.2845.2 ± 67.4110.3 ± 24.5417.0 ± 42.58
Platelets - Week 5228.0 ± 74.2846.1 ± 74.916.6 ± 64.24-2.0 ± 33.85
Platelets - Week 60-19.1 ± 53.4839.0 ± 60.3324.4 ± 65.73-2.8 ± 28.43
SecondaryValue of Protein-creatinine Urinalysis Test to Detect Change From Baseline

Change from baseline in protein-creatinine ratio urinalysis tests are reported.

Time frame:
Baseline to Week 60
Reported as:
Mean · g/g
Value of Protein-creatinine Urinalysis Test to Detect Change From Baseline
g/gAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Protein/Creatinine - Week 121.37029 ± 5.186672-0.13007 ± 1.123807-0.03056 ± 0.0567010.32764 ± 0.337631
Protein/Creatinine - Week 520.03756 ± 0.135157-0.00465 ± 0.183327-0.00781 ± 0.0476710.080930 ± 1.581772
Protein/Creatinine - Week 600.02578 ± 0.119862-0.28836 ± 1.185347-0.03501 ± 0.0618880.46178 ± 0.899886
SecondaryValue of Total Protein Urinalysis Test to Detect Change From Baseline

Change from baseline in total protein urinalysis tests are reported.

Time frame:
Baseline to Week 60
Reported as:
Mean · g/L
Value of Total Protein Urinalysis Test to Detect Change From Baseline
g/LAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Protein, Total - Week 120.7669 ± 2.71221-0.0744 ± 0.764450 ± 00.3443 ± 0.34301
Protein, Total - Week 52-0.0029 ± 0.08124-0.0011 ± 0.334680 ± 00.1143 ± 0.24476
Protein, Total - Week 600.1151 ± 0.12514-0.1790 ± 0.830660.003 ± 0.006710.3975 ± 0.82602
SecondaryValue of Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)

Change from baseline in clinical chemistry blood tests (Alanine Aminotransferase, Aspartate Aminotransferase) are reported.

Time frame:
Baseline to Week 60
Reported as:
Mean · ukat/L
Value of Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)
ukat/LAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Alanine Aminotransferase - Week 120.00769 ± 0.147479-0.13003 ± 0.431764-0.05418 ± 0.0459050.02501 ± 0.134397
Alanine Aminotransferase - Week 52-0.06335 ± 0.119642-0.05607 ± 0.556152-0.06335 ± 0.0477350.04167 ± 0.169182
Alanine Aminotransferase - Week 60-0.01297 ± 0.0431310.09446 ± 0.365981-0.04334 ± 0.032495-0.01667 ± 0.18127
Aspartate Aminotransferase - Week 12-0.01154 ± 0.065765-0.10502 ± 0.1690990.00417 ± 0.0599110.03334 ± 0.105430
Aspartate Aminotransferase - Week 52-0.04834 ± 0.066424-0.05304 ± 0.1963690.00333 ± 0.0908470.09169 ± 0.100482
Aspartate Aminotransferase - Week 60-0.01111 ± 0.0589370.04816 ± 0.1237520 ± 0.050010-0.02501 ± 0.099555
SecondaryValue of Creatinine Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)

Change from baseline in clinical creatinine chemistry blood tests (serum) are reported.

Time frame:
Baseline to Week 60
Reported as:
Mean · umol/L
Value of Creatinine Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)
umol/LAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
Creatinine - Week 124.385 ± 8.5799-3.6 ± 11.24675.5 ± 6.35095.25 ± 9.8446
Creatinine - Week 5212.2 ± 33.2597-7.273 ± 19.58620.2 ± 13.97142.5 ± 5.5076
Creatinine - Week 607.316 ± 8.7449-5.556 ± 12.84635.0 ± 10.41636.5 ± 12.5033
SecondaryValue of Inflammatory Marker Panel Blood Tests to Detect Change From Baseline

Change from baseline in the Erythrocyte Sedimentation Rate (ESR) inflammatory marker is reported.

Time frame:
Baseline to Week 60
Reported as:
Mean · mm
Value of Inflammatory Marker Panel Blood Tests to Detect Change From Baseline
mmAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
ESR - Week 12-3.0 ± 20.37-7.2 ± 15.46-11.9 ± 15.36
ESR - Week 525.6 ± 25.58-6.7 ± 12.25-16.0 ± 10.95
ESR - Week 6014.6 ± 38.77-1.0 ± 21.842.2 ± 22.48
SecondaryValue of Autoantibody Blood Panel Blood Tests to Detect Change From Baseline

Change from baseline in Anti-Double Stranded DNA IgG (anti-dsDNA) is reported.

Time frame:
Baseline to Week 60
Reported as:
Mean · IU/mL
Value of Autoantibody Blood Panel Blood Tests to Detect Change From Baseline
IU/mLAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator to Lower DosePlacebo Comparator to Higher Dose
anti-dsDNA - Week 12-42.09 ± 256.228-84.97 ± 231.489-37.0 ± 19.799-97.33 ± 151.596
anti-dsDNA - Week 52-99.04 ± 288.1838.70 ± 27.308-13.0 ± 50.229-76.87 ± 127.433
anti-dsDNA - Week 6052.67 ± 144.22016.53 ± 30.528-21.33 ± 54.921-76.73 ± 141.525
SecondaryNumber of Participants With Positive Hepatitis B Core Antibody Post-baseline.

Change from screening in Hepatitis B core antibody was monitored during the study for participants tested positive at screening.

Time frame:
Baseline to Week 60

No measurements were reported for this outcome.

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anifrolumab - Lower Dose0/14 (0%)4/14 (28.6%)12/14 (85.7%)
Anifrolumab - Higher Dose0/13 (0%)2/13 (15.4%)11/13 (84.6%)
Placebo Comparator0/9 (0%)0/9 (0%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
EventAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
Systemic Lupus ErythematosusMusculoskeletal and connective tissue disorders1/141/130/9
Lupus NephritisRenal and urinary disorders1/141/130/9
Herpes ZosterInfections and infestations1/140/130/9
Otitis Media AcuteInfections and infestations1/140/130/9
Transient Ischaemic AttackNervous system disorders1/140/130/9
Mouth UlcerationGastrointestinal disorders1/140/130/9
Most frequent other events
Showing 10 of 69
Most frequent other events
EventAnifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo Comparator
Upper Respiratory Tract InfectionInfections and infestations5/141/133/9
BronchitisInfections and infestations1/143/131/9
DiarrhoeaGastrointestinal disorders2/140/132/9
NasopharyngitisInfections and infestations3/142/131/9
HeadacheNervous system disorders2/142/130/9
SciaticaNervous system disorders0/142/130/9
Herpes ZosterInfections and infestations2/140/131/9
Back PainMusculoskeletal and connective tissue disorders2/141/131/9
Abscess LimbInfections and infestations0/140/131/9
SinusitisInfections and infestations0/140/131/9

Baseline characteristics

Includes all participants randomized into the study who receive at least one dose of investigational product, according to randomized treatment (modified Intention-To-Treat).

Age, Continuous
Age, Continuous(years)Anifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo ComparatorTotal
Mean46.3 ± 9.141.5 ± 9.247.8 ± 14.244.9 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Anifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo ComparatorTotal
Female1212832
Male2114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Anifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo ComparatorTotal
Hispanic or Latino0000
Not Hispanic or Latino1413936
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Anifrolumab - Lower DoseAnifrolumab - Higher DosePlacebo ComparatorTotal
American Indian or Alaska Native0000
Asian6208
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White811928
More than one race0000
Unknown or Not Reported0000
08

Study locations

14 sites
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Orlando, Florida 32810, United States
  • Research Site
    New York, New York 10019, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Houston, Texas 77034, United States
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
  • Research Site
    Anyang-si, 14068, Korea, Republic of
  • Research Site
    Busan, 49241, Korea, Republic of
  • Research Site
    Daegu, 41944, Korea, Republic of
  • Research Site
    Gwangju, 61469, Korea, Republic of
  • Research Site
    Bydgoszcz, 85-168, Poland
  • Research Site
    Warszawa, 00-874, Poland
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jan 2018, 11 months.

Results were first posted in Dec 2019, 1 year 10 months after primary completion. A results delay was requested in Sep 2018.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 11 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2016
First posted
Nov 15, 2016
StartActual
Feb 14, 2017
Primary completionActual
Jan 22, 2018
CompletionActual
Dec 17, 2018
Results delay requested
Sep 4, 2018
Results first posted
Dec 18, 2019
Last update
Jan 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02962960
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Feb 14, 2017
Primary completion
Jan 22, 2018
Completion
Dec 17, 2018
Results posted
Dec 18, 2019
Last update
Jan 12, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion